US Halts New Patients on Merck’s MS Drug, Shares Dive

Published on April 12, 2023

Merck KGaA said on Wednesday the U.S. Food and Drug Administration (FDA) had paused the initiation of new patients on its multiple sclerosis evobrutinib drug, knocking the German drugmaker’s share price. Merck has been ahead in the race to develop a drug from the class known…

Read Full Article (External Site)